A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.
Natalie TurnerMattia ForcatoSimona NuzzoLuca MalorniSilvio BicciatoAngelo Di LeoPublished in: NPJ breast cancer (2015)
With further validation, ConSig1 may help refine selection of TNBC patients for anthracycline chemotherapy.